debrisoquin has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ray-Chaudhuri, K | 1 |
| Smith, C | 1 |
| Gough, AC | 1 |
| Novak, N | 1 |
| Chamoun, V | 1 |
| Wolf, CR | 1 |
| Leigh, PN | 1 |
1 other study available for debrisoquin and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis.
Topics: Acetyltransferases; Amyotrophic Lateral Sclerosis; Cytochrome P-450 Enzyme System; Debrisoquin; Geno | 1995 |